At initiation of ipilimumab treatment in October 2013 for disseminated melanoma, the patient was a 51-year-old man diagnosed with HIV in 1986 and with a CD4 + nadir of 159 cells/μl in 1995. He was on ART since 1996 and plasma HIV RNA was less than 400 copies/ml from 2004 and less than 20 copies/ml from July 2012 ( Fig. 1a ). He received four doses of ipilimumab 3 mg/kg given at three-weekly intervals.
Whilst receiving ipilimumab, there was no overall change in plasma HIV RNA as measured by the Roche viral load assay [lower limit of detection (LLOD) = 20 copies/ml; Fig. 1c ]. Using a sensitive single-copy HIV RNA assay (SCA) (LLOD = 0.3 copies/ml) [9] , there was a cyclical decrease in plasma HIV RNA following each infusion and an overall decline from 60 to 5 copies/ml ( Fig. 1c ). Given more frequent sampling was performed with the SCA, we believe that longitudinal changes over time were best assessed with this assay.
There was an increase in CD4 + T cells after each infusion (overall change from 610 to 900 cells/μl) ( Fig. 1b ). This increase was predominantly in total memory ( Fig. 1d ) and effector memory CD4 + T cells ( Fig. 1e ). Postinfusion increases in CD4 + T-cell activation were seen as measured by human leukocyte antigen-DR and CD38 and CCR5 expression ( Fig. 1f ). There were transient increases in CD8 + T cells following the second and third infusions, but no overall change in CD8 + T cell activation ( Fig. 1g ).
Cell-associated unspliced HIV RNA in sorted CD4 + T cells was quantified with increases observed following the first and second infusions, with a maximum change from baseline of 19.6-fold (Fig. 1h ). The changes in cell-associated unspliced HIV RNA was greater than those recently reported, following the administration of the histone deacetylase inhibitors vorinostat [10, 11] or panobinostat [12] , or following disulfiram [13] .
There was no change in cell-associated HIV DNA (Fig. 1i ), but any change in the small proportion of cells with HIV DNA containing inducible proviruses [14] may not have been detectable with the assays used here.
Acknowledging the limitations deriving from this being a single case, we speculate the increase in cell-associated unspliced RNA could have been due to mechanisms, including an increase in HIV RNA transcription secondary to blocking the inhibitory effects of CTLA-4 on T cell transcription, similar to that described following ex-vivo anti-PD1 treatment of CD4 + T cells from HIV-infected patients on ART [15] ; redistribution or expansion of effector memory CD4 + T cells that may have a higher ratio of cell-associated HIV RNA to HIV DNA [16] (Satish Pillai, San Francisco, UCSF, San Francisco, California, personal communication); or redistribution or expansion of activated T cells including Tregs. The increase in cell-associated unspliced HIV RNA and decline in SCA was intriguing, perhaps mediated by elimination of latently infected CD4 + T cells that were induced to express viral antigens. But the rapidity of the decline in SCA makes this somewhat unlikely.
Blockade of CTLA-4 with ipilimumab in an HIV-infected patient on ART had significant effects on the total number and phenotype of CD4 + T cells and induced a profound increase in cell-associated unspliced HIV RNA with onset after the first dose and was associated with subsequent decline in plasma HIV RNA. Further studies are warranted to determine if ipilimumab could play a role in eliminating latently infected cells in HIV-infected patients on ART. 
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